Abbonarsi

Joint involvement in Noonan syndrome. A retrospective paediatric descriptive study - 02/01/22

Doi : 10.1016/j.jbspin.2021.105270 
Aurore Le Quellec a, Thomas Edouard b, Séverine Audebert-Bellanger c, Antoine Pouzet c, Karine Bourdet d, Cindy Colson e, Charlotte Oriot f, Sylvaine Poignant f, Alain Saraux a, b, c, d, e, f, g, Valérie Devauchelle-Pensec a, b, c, d, e, f, g,
a Rheumatology department, Center of Autoimmune Rare Diseases (CERAINO), CHU Cavale Blanche, Brest, France 
b Endocrinology, bone diseases and genetics unit, hôpital des Enfants, CHU de Toulouse, France 
c Pediatric and genetic department, CHU Morvan, Brest, France 
d Pediatric department, CHU Morvan, Brest, France 
e Genetic department, CHU de Caen, France 
f Pediatric and genetic department, CHU de Nantes, France 
g UMR1227, Inserm, université de Bretagne Occidentale, Brest, France 

Corresponding author at: Service de rhumatologie, CHU Cavale Blanche, boulevard Tanguy-Prigent, 29200 Brest, France.Service de rhumatologie, CHU Cavale Blancheboulevard Tanguy-PrigentBrest29200France

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 6
Iconografia 1
Video 0
Altro 0

Highlights

In Noonan syndrome, joint symptoms appear during childhood.
Musculoskeletal pain are present in 25 % of the patients and joint stiffness in 14 %.
The knees and the elbows, are the more affected joints.
Treatment with GH and SOS1 mutations was significantly related to the occurrence of musculoskeletal pain.
Villonodular synovitis is severe and more frequently multifocal but rare.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Objectives

Noonan syndrome is a rare genetic disorder characterized mainly by congenital heart disease, occasional intellectual disability, and varied orthopaedic, rheumatological and haematologic anomalies. Despite potentially serious functional consequences, joint involvement has been rarely studied in the literature. Our objective was to perform a retrospective study evaluating the prevalence and characteristics of joint involvement in Noonan syndrome.

Methods

We recorded articular symptoms, including their type and frequency, in patients with Noonan syndrome followed up in French hospitals. Patients were included if the diagnosis was confirmed before the age of 20 based on the van der Burgt criteria or genetic analysis. Data are presented as frequencies or medians (ranges), and patient groups were compared using chi-square or Fisher tests.

Results

Seventy-one patients were included from 4 centres. The average age was 12.5 years (range: 2–36). Musculoskeletal pain was found in 18 patients (25%) and joint stiffness in 10 (14%) located in the wrists, elbows, ankles, knees and hips, which was usually bilateral. Only one destructive form was described (multiple villonodular synovitis and a giant cell lesion of the jaw). There were no cases of systemic lupus erythaematosus (SLE) or other autoimmune arthritis. Raynaud's phenomenon was observed in 3 patients. Only 50% of joint complaints led to additional exploration. SOS1 mutations (P<0.05) and treatment with growth hormone (GH) (P<0.05) were the only factors significantly related to musculoskeletal pain. Patients treated with GH did not have more SOS1 mutations. Patients experiencing pain were not more likely to experience stiffness, joint hypermobility, or coagulation abnormalities.

Conclusion

Joint manifestations were frequent in Noonan syndrome, predominant in large joints, and rarely explored. Multiple villonodular synovitis is characteristic but rare. Auto-immune disorders were not described in this cohort. A more multidisciplinary approach could be recommended for the early detection of possibly disabling rheumatologic manifestations.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Joint involvement, Pigmented villonodular synovitis, Central giant cell granuloma, Noonan Syndrome, RASopathy


Mappa


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 89 - N° 1

Articolo 105270- Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases
  • Neus Quilis, Francisca Sivera, Daniel Seoane-Mato, Fernando Pérez-Ruiz, Carlos Sánchez-Piedra, Federico Díaz-González, Sagrario Bustabad-Reyes, Working Group Proyecto EPISER2016
| Articolo seguente Articolo seguente
  • Successive new-pathogen prosthetic joint reinfections: Observational cohort study on 61 patients
  • Caroline Béal, Valérie Zeller, Younes Kerroumi, Vanina Meyssonnier, Beate Heym, Pascal Chazerain, Simon Marmor

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.